• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

October 28-29, 2010 Transmissible Spongiform Encephalopathies Advisory Committee Meeting Draft Agenda

DRAFT AGENDA

Transmissible Spongiform Encephalopathies Advisory Committee
22nd Meeting, October 28-29, 2010

The Holiday Inn Gaithersburg
2 Montgomery Village Avenue
Gaithersburg, MD 20879

Thursday, October 28, 2010

8:30a.m.Opening Remarks, Chair, TSEAC
Statement of Conflicts of Interest, Announcements
8:40 a.m.

Topic I: Review of FDA’s Risk Assessment for Potential Exposure to Variant Creutzfeldt-Jakob Disease in U.S.-licensed Plasma-Derived Factor VIII

  1. Introduction, Steven Anderson, Ph.D., OBE, FDA (30’)
  2. Presentation of FDA Risk Assessment, Hong Yang, Ph.D., OBE, FDA (40’)
  3. Summary and Questions for the Committee, Steven Anderson, Ph.D., OBE, FDA (20’)
10:30 a.m.Break
10:45 a.m.Open Public Hearing
11:30 a.m.

Open Committee Discussion

Questions for the Committee

12:30 p.m.Lunch
1:45 p.m.

Topic II: Labeling of Plasma-derived Products, including Plasma-derived Albumin and Products Containing Plasma-derived Albumin to Address the Possible Risk of Transmission of V ariant Creutzfeldt-Jakob Disease

  1. Introduction and Rationale for Proposed Labeling Change for Plasma Derivatives to Reflect Possible vCJD Risk Dorothy Scott, M.D., DH, OBRR, FDA (15’)
  2. TSE Clearance in Manufacturing of Plasma Derivatives, PPTA (25’)
  3. Summary and Questions for the Committee Dorothy Scott, M.D., DH, OBRR, FDA (20’)
2:45 p.m.Break
3:00 p.m.Open Public Hearing
3:30 p.m.

Open Committee Discussion

Questions for the Committee

4:30 p.m.Adjournment

Friday, October 29, 2010

8:30 a.m.

Opening Remarks, Chair, TSEAC

Statement of Conflicts of Interest, Announcements

8:40 a.m.

Informational Presentations: FDA’s Geographic Donor Deferral Policy to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products and Human Cells, Tissues and Cellular and Tissue-based Products

  • Review of Current FDA Policies
    • David Asher, M.D., DETTD, OBRR, FDA (30’)
    • Elizabeth Lybarger, M.F.S., M.S. LT USPHS, DHT, OCTGT, FDA (15’)
  • Variant CJD in the UK and Worldwide, Robert Will, M.D., UK CJD Surveillance Unit, Edinburgh (30’)
  • BSE in the USA and Worldwide, Linda Detwiler, D.V.M., University of Mississippi (15’)
  • USDA Updates
    • Christopher Robinson, D.V.M., National Center for Import and Export, APHIS, USDA (15’)
    • Troy Bigelow, D.V.M, National Center for Animal Health Programs, APHIS, USDA (15’)
  • Questions to Speakers (10’)
11:00 a.m.Open Public Hearing
11:30 a.m.Break
11:45 a.m.

Committee Updates

  1. Recent Advances in Development of Devices to Remove TSE Agents from Blood Components.
    1. Steven J. Burton, Ph.D., Prometric BioSciences, Ltd. (15’)
    2. Sam Coker, Ph.D., Pall Medical Corporation (15’)
    3. Tomo Yokomizo, M.Sc., Asahi-Kasei Medical (15’)
  2. Questions to Speakers (10’)
12:30 p.m.Adjournment